Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gallium Ga 68-THP-PSMA

A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting agent conjugated, via the tris(hydroxypyridinone) (THP) chelator, to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-THP-PSMA, the PSMA moiety targets and binds to PSMA-expressing tumor cells. Upon PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:gallium Ga 68-labeled THP-PSMA
gallium Ga 68-tris(hydroxypyridinone)-prostate-specific membrane antigen
Abbreviation:68Ga-THP-PSMA
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search